利巴维林治疗血造干细胞移植和肺移植患者的帕拉米克索病毒感染:优化剂量方案的评估
Manon C Wilpshaar1, Berdien Oortgiesen1, Martijn Bakker2
1Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
一种新的固定剂量利巴维林疗法改善了帕拉米克索病毒感染的移植患者的治疗药物度. 与传统基于体重的方法相比,这种优化剂量策略显示出更好的疗效和降低发烧.
科学领域:
- 药理学 药理学是指药理学的学科.
- 传染性疾病 传染性疾病
- 移植医学 移植医学 移植医学
背景情况:
- 利巴维林对于治疗干细胞和肺移植接受者的帕拉米克索病毒感染至关重要.
- 目前基于体重的剂量方案对最佳治疗度缺乏明确性.
- 这项研究解决了改善利巴维林剂量策略的需求.
研究的目的:
- 开发和评估一个优化的固定剂量利巴维林治疗方案.
- 为了比较固定剂量治疗方案与传统基于体重的治疗方案的疗效.
- 评估移植受体的目标实现和临床结果.
主要方法:
- 用药理动力学模拟来优化基于体重的疗法,将其转化为固定剂量疗法.
- 一项追溯观察队列研究比较了基于体重和固定的剂量方案.
- 患者包括干细胞和肺移植接受者,患有呼吸道同胞病毒,人类甲肺病毒或偏流感病毒感染.
主要成果:
- 固定剂量治疗方案在59%的患者中实现了治疗性利巴维林度,而基于体重的治疗方案则为13% (P=0.001).
- 在固定剂量组中,第三天的发烧显著降低 (5%对30%;P=0.034).
- 固定的剂量疗法显示了减少住院时间和死亡率的趋势.
结论:
- 建议的固定剂量利巴维林疗法在达到目标度方面比传统的基于体重的疗法更有效.
- 这种优化的剂量策略为移植患者提供了改善的治疗结果.
- 进一步的研究可能会证实减少住院和死亡率的好处.
更多相关视频
11:18Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus
Published on: May 7, 2012
08:04Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
Published on: July 9, 2014
相关概念视频
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Acute Respiratory Failure-IV
Myocarditis III: Medical Management
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
